• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与囊性纤维化患者 FEV1 下降相关的因素:对 ECFS 患者注册中心的分析。

Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.

机构信息

Hadassah Hebrew University Hospital, Jerusalem, Israel.

出版信息

Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18.

DOI:10.1183/09031936.00166412
PMID:23598952
Abstract

Pulmonary insufficiency is the main cause of death in cystic fibrosis (CF). We analysed forced expiratory volume in 1 s (FEV1) data of 14,732 patients registered in the European Cystic Fibrosis Society Patient Registry (ECFSPR) database in 2007. We used linear and logistic regressions to investigate associations between FEV1 % predicted and clinical outcomes. Body mass index (BMI), chronic infection by Pseudomonas aeruginosa, pancreatic status and CF-related diabetes (CFRD) showed a statistically significant (all p<0.0001) and clinically relevant effect on FEV1 % pred after adjusting for age. Patients with a lower BMI experience a six-fold increased odds ratio (95% CI 5.0-7.3) of having severe lung disease (FEV1 <40% pred) compared to patients with normal BMI. Being chronically infected with P. aeruginosa increases the odds ratio of severe lung disease by 2.4 (95% CI 2.0-2.7), and patients with pancreatic insufficiency experience a 2.0-fold increased odds ratio (95% CI 1.6-2.5) of severe lung disease compared to pancreatic sufficient patients. Patients with CFRD have a 1.8-fold increased odds ratio (95% CI 1.6-2.2) compared to patients not affected. These potential risk factors for pulmonary disease in patients with CF are to some degree preventable or treatable. We emphasise the importance of their early identification through frequent routine tests, the implementation of infection control measures, and a timely initiation of relevant therapies.

摘要

肺功能不全是囊性纤维化(CF)患者的主要死亡原因。我们分析了 2007 年欧洲囊性纤维化协会患者注册数据库(ECFSPR)中登记的 14732 名患者的 1 秒用力呼气量(FEV1)数据。我们使用线性和逻辑回归分析来研究 FEV1%预测值与临床结局之间的关联。调整年龄后,体重指数(BMI)、铜绿假单胞菌慢性感染、胰腺状态和 CF 相关糖尿病(CFRD)与 FEV1%预测值均有统计学意义(均 P<0.0001)且具有临床相关性。与 BMI 正常的患者相比,BMI 较低的患者发生严重肺部疾病(FEV1<40%预测值)的可能性增加了六倍(95%CI 5.0-7.3)。慢性铜绿假单胞菌感染使严重肺部疾病的比值比增加了 2.4(95%CI 2.0-2.7),而与胰腺功能正常的患者相比,胰腺功能不全的患者发生严重肺部疾病的可能性增加了 2.0 倍(95%CI 1.6-2.5)。与未受影响的患者相比,CFRD 患者发生严重肺部疾病的比值比增加了 1.8 倍(95%CI 1.6-2.2)。这些 CF 患者肺部疾病的潜在危险因素在某种程度上是可以预防或治疗的。我们强调通过频繁的常规检查、实施感染控制措施以及及时开始相关治疗来早期识别这些危险因素的重要性。

相似文献

1
Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.与囊性纤维化患者 FEV1 下降相关的因素:对 ECFS 患者注册中心的分析。
Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18.
2
Chronic Pseudomonas aeruginosa infection and respiratory muscle impairment in cystic fibrosis.囊性纤维化患者中慢性铜绿假单胞菌感染与呼吸肌功能障碍。
Respir Care. 2014 Mar;59(3):363-70. doi: 10.4187/respcare.02549. Epub 2013 Aug 27.
3
Increased rate of lung function decline in Australian adolescents with cystic fibrosis.澳大利亚囊性纤维化青少年肺功能下降率增加。
Pediatr Pulmonol. 2014 Sep;49(9):873-7. doi: 10.1002/ppul.22946. Epub 2013 Oct 31.
4
Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.烟曲霉和铜绿假单胞菌的共同定植与囊性纤维化患者较差的健康状况相关:一项爱尔兰登记分析。
BMC Pulm Med. 2017 Apr 21;17(1):70. doi: 10.1186/s12890-017-0416-4.
5
Clinical expression of cystic fibrosis in a large cohort of Italian siblings.意大利大样本同胞队列中囊性纤维化的临床表型。
BMC Pulm Med. 2018 Dec 22;18(1):196. doi: 10.1186/s12890-018-0766-6.
6
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients.慢性嗜麦芽窄食单胞菌感染与囊性纤维化患者的死亡率或肺移植。
J Cyst Fibros. 2013 Sep;12(5):482-6. doi: 10.1016/j.jcf.2012.12.006. Epub 2013 Jan 5.
7
Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al.囊性纤维化相关性糖尿病在欧洲的流行情况、风险因素和结局;Olesen 等人。
J Cyst Fibros. 2020 Mar;19(2):321-327. doi: 10.1016/j.jcf.2019.10.009. Epub 2019 Oct 31.
8
Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis.胰腺酶替代疗法剂量与囊性纤维化患儿营养结局的关系。
J Pediatr. 2014 May;164(5):1110-1115.e1. doi: 10.1016/j.jpeds.2014.01.022. Epub 2014 Feb 20.
9
Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study.与土耳其囊性纤维化登记处患者肺功能下降相关的因素:一项回顾性队列研究。
Pediatr Pulmonol. 2024 Nov;59(11):2956-2966. doi: 10.1002/ppul.27165. Epub 2024 Jul 9.
10
Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes.金黄色葡萄球菌和铜绿假单胞菌共感染与囊性纤维化相关糖尿病及不良临床结局有关。
Eur J Clin Microbiol Infect Dis. 2016 Jun;35(6):947-53. doi: 10.1007/s10096-016-2621-0. Epub 2016 Mar 18.

引用本文的文献

1
Evolution and Prognostic Variables of Cystic Fibrosis in Children and Young Adults: A Narrative Review.儿童和青年囊性纤维化的演变及预后变量:一项叙述性综述
Diagnostics (Basel). 2025 Aug 2;15(15):1940. doi: 10.3390/diagnostics15151940.
2
Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry.囊性纤维化患者接受依列卡福/替扎卡福/依伐卡福治疗后的呼吸道感染:欧洲囊性纤维化协会患者登记处分析
ERJ Open Res. 2025 Aug 4;11(4). doi: 10.1183/23120541.01248-2024. eCollection 2025 Jul.
3
A chronic mouse lung infection modeling the mucus obstruction, lung function, and inflammation of human cystic fibrosis.
一种模拟人类囊性纤维化的黏液阻塞、肺功能和炎症的慢性小鼠肺部感染模型。
Infect Immun. 2025 Jun 13:e0023025. doi: 10.1128/iai.00230-25.
4
State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists.最新综述:囊性纤维化患者护理的变革性变化:对传染病专家的启示
Clin Infect Dis. 2025 Jun 4;80(5):e65-e77. doi: 10.1093/cid/ciaf009.
5
Impact of appetite stimulants on growth parameters in children with cystic fibrosis.食欲刺激剂对囊性纤维化患儿生长参数的影响。
Eur J Clin Nutr. 2025 Jul;79(7):685-689. doi: 10.1038/s41430-025-01591-4. Epub 2025 Mar 1.
6
Progression and mortality of patients with cystic fibrosis in China.中国囊性纤维化患者的疾病进展与死亡率
Orphanet J Rare Dis. 2025 Jan 7;20(1):6. doi: 10.1186/s13023-024-03522-1.
7
Modifies Chronic Airway Infection Risk in Cystic Fibrosis.改变囊性纤维化患者慢性气道感染风险。
Ann Am Thorac Soc. 2025 May;22(5):715-723. doi: 10.1513/AnnalsATS.202408-868OC.
8
Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income Countries.扩大新型囊性纤维化疗法在低收入和中等收入国家的影响。
Pediatr Pulmonol. 2025 Mar;60 Suppl 1(Suppl 1):S90-S91. doi: 10.1002/ppul.27362. Epub 2024 Dec 3.
9
A chronic mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis.一种模拟人类囊性纤维化病理生理学和炎症的慢性小鼠肺部感染模型。
bioRxiv. 2024 Oct 7:2024.10.07.617039. doi: 10.1101/2024.10.07.617039.
10
Factors associated with cystic fibrosis mortality before the age of 30: retrospective analysis of a cohort in southern Brazil.与 30 岁前囊性纤维化死亡相关的因素:巴西南部队列的回顾性分析。
Braz J Med Biol Res. 2024 Aug 23;57:e13476. doi: 10.1590/1414-431X2024e13476. eCollection 2024.